BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37452993)

  • 1. Mirroring UC care pathways in refractory immune checkpoint inhibitor (ICI)-mediated colitis: distinct features and common pathways.
    Sleiman J; Brand RM; Pai R; Brand RE; Rhee J; Schwartz M; Davar D
    Clin J Gastroenterol; 2023 Oct; 16(5):680-684. PubMed ID: 37452993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study.
    Abu-Sbeih H; Ali FS; Alsaadi D; Jennings J; Luo W; Gong Z; Richards DM; Charabaty A; Wang Y
    J Immunother Cancer; 2018 Dec; 6(1):142. PubMed ID: 30518410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis.
    Abu-Sbeih H; Herrera LN; Tang T; Altan M; Chaftari AP; Okhuysen PC; Jenq RR; Wang Y
    J Immunother Cancer; 2019 Sep; 7(1):242. PubMed ID: 31488205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of immune checkpoint inhibitor-mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score-matched retrospective study.
    Sleiman J; Wei W; Shah R; Faisal MS; Philpott J; Funchain P
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34158318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Checkpoint Inhibitor-Mediated Diarrhea and Colitis: A Clinical Review.
    Gong Z; Wang Y
    JCO Oncol Pract; 2020 Aug; 16(8):453-461. PubMed ID: 32584703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis.
    Abu-Sbeih H; Ali FS; Naqash AR; Owen DH; Patel S; Otterson GA; Kendra K; Ricciuti B; Chiari R; De Giglio A; Sleiman J; Funchain P; Wills B; Zhang J; Naidoo J; Philpott J; Gao J; Subudhi SK; Wang Y
    J Clin Oncol; 2019 Oct; 37(30):2738-2745. PubMed ID: 31163011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study.
    Zou F; Faleck D; Thomas A; Harris J; Satish D; Wang X; Charabaty A; Ernstoff MS; Glitza Oliva IC; Hanauer S; McQuade J; Obeid M; Shah A; Richards DM; Sharon E; Wolchok J; Thompson J; Wang Y
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34789551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of Immune Checkpoint Inhibitor-related Diarrhea or Colitis in Cancer Patients With Superimposed Gastrointestinal Infections.
    Ma W; Gong Z; Abu-Sbeih H; Peng Y; Peng F; Zou F; Charabaty A; Okhuysen PC; McQuade JL; Altan M; Zhang HC; Thomas AS; Wang Y
    Am J Clin Oncol; 2021 Aug; 44(8):402-408. PubMed ID: 34107499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review.
    Nakane T; Mitsuyama K; Yamauchi R; Kakuma T; Torimura T
    Kurume Med J; 2023 Jul; 68(2):43-52. PubMed ID: 37100606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-Gamma-Producing CD8
    Sasson SC; Slevin SM; Cheung VTF; Nassiri I; Olsson-Brown A; Fryer E; Ferreira RC; Trzupek D; Gupta T; Al-Hillawi L; Issaias ML; Easton A; Campo L; FitzPatrick MEB; Adams J; Chitnis M; Protheroe A; Tuthill M; Coupe N; Simmons A; Payne M; Middleton MR; Travis SPL; ; Fairfax BP; Klenerman P; Brain O
    Gastroenterology; 2021 Oct; 161(4):1229-1244.e9. PubMed ID: 34147519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementing an immunotherapy toxicity (IOTOX) GI service improves outcomes in patients with immune-mediated diarrhea and colitis.
    Saji A; Chopra M; Jacob J; Altan M; Alhalabi O; Shah AY; Qiao W; Wang Y; Thomas A
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):5841-5852. PubMed ID: 36585982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of C-Reactive Protein in Predicting the Severity and Response of Immune-Mediated Diarrhea and Colitis in Patients with Cancer.
    Liu C; Shatila M; Mathew A; Machado AP; Thomas A; Zhang HC; Thomas AS; Faleck D; Funchain P; Philpott J; Grivas P; Obeid M; Carbonnel F; Wang Y
    J Cancer; 2023; 14(10):1913-1919. PubMed ID: 37476185
    [No Abstract]   [Full Text] [Related]  

  • 13.
    Vasavada S; Panneerselvam K; Amin R; Varatharajalu K; Okhuysen PC; Oliva ICG; Wang J; Grivas P; Thomas AS; Wang Y
    Ann Gastroenterol; 2022; 35(4):393-399. PubMed ID: 35784625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcineurin inhibitors in steroid and anti-TNF-alpha refractory immune checkpoint inhibitor colitis.
    Zhang E; Kiely C; Sandanayake N; Tattersall S
    JGH Open; 2021 May; 5(5):558-562. PubMed ID: 34013054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Checkpoint Inhibitor Colitis With Superimposed Clostridioides difficile Infection.
    Mohammad AW; Kusnik A; Mostafa MR; Tan J; Strapko A
    Cureus; 2023 Apr; 15(4):e37006. PubMed ID: 37139037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis.
    Kaneoka A; Okada E; Sugino H; Saito-Sasaki N; Omoto D; Nakamura M
    Diagnostics (Basel); 2022 Feb; 12(2):. PubMed ID: 35204571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P067 Immune Checkpoint Inhibitor Colitis in a Community-Based Hospital System.
    Rampersad A; Abrams G; Bauer C
    Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S17-S18. PubMed ID: 37461984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response.
    Zou F; Abu-Sbeih H; Ma W; Peng Y; Qiao W; Wang J; Shah AY; Glitza Oliva IC; Piha-Paul SA; Thompson JA; Zhang HC; Thomas AS; Wang Y
    J Natl Compr Canc Netw; 2020 Dec; 19(6):700-708. PubMed ID: 33316767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitor-induced colitis: A comprehensive review.
    Som A; Mandaliya R; Alsaadi D; Farshidpour M; Charabaty A; Malhotra N; Mattar MC
    World J Clin Cases; 2019 Feb; 7(4):405-418. PubMed ID: 30842952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint Inhibitor-Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis.
    Nielsen DL; Juhl CB; Chen IM; Kellermann L; Nielsen OH
    Cancer Treat Rev; 2022 Sep; 109():102440. PubMed ID: 35917654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.